Introduction
============

Panic attacks (PA) are periods of intense fear concomitant with other symptoms such as breathing difficulties and palpitations. PAs are most commonly associated with panic disorder (PD), but are also severity specifiers for all mental disorders in the Diagnostic and Statistical Manual of Mental disorders (DSM-5) ([@B1]). Currently, diagnoses of psychiatric disorders are based on the presence of symptoms specified in the DSM. Individuals with very heterogeneous clinical manifestations can meet the required minimum number of symptoms for a disorder and thus receive the same diagnosis and treatment. However, the same treatment might not be equally efficient in these patients. The [@B76] initiated a new research framework, the Research Domain Criteria (RDoC), to classify mental disorders based on dimensions of dysfunction in neurobiological and psychological circuits. By integrating diverse approaches such as molecular circuits and genetics, the translation of fundamental findings to the clinic can be facilitated. It can lead to a better understanding of which functions underlie a specific behavior or symptom, and what degree of dysregulation is associated with a shift from mental health to subclinical presentation and, ultimately, full disorder level. Eventually, this could support establishing a graded classification that opens new approaches for more precise treatment strategies. This mini review provides an overview of methodologies used to assess PAs in the clinic and in the laboratory focusing on carbon dioxide (CO~2~) exposure, and discusses added value and approaches for real-life assessment and epigenetic research.

Panic Attacks in the Clinic
===========================

The diagnostic criteria for PAs and PD are specified in the DSM ([@B1]) and serve as guideline for clinicians. Currently, PAs are defined as sudden episodes of intense fear or discomfort, reaching a peak within minutes and accompanied by at least four of 13 symptoms: palpitations, sweating, trembling or shaking, breathlessness, feeling of choking, chest pain, nausea, dizziness, chills or heat sensations, paresthesia, derealization or depersonalization, fear of losing control or going crazy, and fear of dying. PD is characterized by recurrent unexpected PAs, followed by at least 1 month of persistent concerns about the occurrence of future attacks or their consequences, and/or strong maladaptive behavioral changes related to the attacks such as avoiding places and situations. Assessment of these symptoms and behavior is classically based on patients' self-reports (interviews and rating scales covering presence and intensity of symptoms, frequency of PAs, impairments in daily life), sometimes completed by clinicians' behavioral observations. Furthermore, a complete psychiatric and medical examination are done to exclude that PAs occur due to, e.g., specific phobia, substance abuse or another medical condition such as thyroid dysfunction. Additional assessment of family history, recent life events, and stress can provide a glance at factors associated with PAs and PD. However, this is insufficient to increase our understanding of molecular alterations and disturbances that make someone vulnerable to develop disorders.

Panic Attacks in the Laboratory
===============================

CO~2~ Exposure as Experimental Model
------------------------------------

To gain insights into the pathophysiology of PAs many studies have made use of experimental panic provocation. Among the many agents used in the laboratory particularly CO~2~ exposure is one of the best validated and most widely used models ([@B58]). Commonly, CO~2~ is administered through a nasal-oral facemask and participants rate their symptoms using questionnaires. Particularly 35% CO~2~ effectively induces DSM specified symptoms ([@B34]) that are in striking resemblance to real-life PA ones ([@B35]; [@B99]), indicating that an acute disturbance of the acid-base homeostasis might be the mechanism underlying PAs as we previously proposed ([@B25]). PD patients react significantly stronger to CO~2~ than patients of many other disorders ([@B110]; [@B79]; [@B56]) with the exception of post-traumatic stress disorder patients who are also reactive to CO~2~ ([@B74]; [@B53]). Additionally, social anxiety disorder patients show an intermediate reactivity between healthy individuals and PD patients ([@B100]). This suggests that some altered mechanisms are common among these disorders.

### Physiology of Panic Attacks

Given the pronounced physiological symptoms of PAs, research has aimed at obtaining detailed insights into bodily changes during attacks. Breathing 35% CO~2~ led to an increase in heart rate in some studies ([@B85]; [@B91]), while others observed an overall decrease ([@B2]; [@B52]; [@B115]). General autonomic arousal is suggested by strong increases in systolic ([@B115]; [@B91]; [@B61]) and diastolic blood pressure ([@B91]; [@B61]). High blood pressure can activate a negative feedback loop, the baroreflex, which causes heart rate to decrease to subsequently lead to a reduction in blood pressure. This might explain the reported heart rate reduction in some studies. Some studies reported increases in heart rate; these varying results might be due to differences in methodology (temporal resolution, age and sex of participants, averaging time points).

CO~2~ is a major activator of breathing in mammals and exerts its effects mainly through activation of central chemoreceptors ([@B87]). Inhaling 35% CO~2~ strongly increased minute ventilation and tidal volume ([@B11]). No difference in the degree of increase could be found between PD patients and healthy individuals, which, however, could have been masked by relatively long analysis epochs of 15 s. Regarding breathing, a distinct respiratory subtype was described that is characterized by a high number of respiratory symptoms during PAs and a higher response to CO~2~ ([@B28]). Non-medicated patients also had a higher variability in respiration rate and partial CO~2~ pressure compared to medicated patients and healthy individuals in the 10 min after the inhalation. Sample sizes were small, but these results might be indicative of a less effective homeostatic control in response to a stimulus such as CO~2~ that acutely disturbs the pH balance in PD patients ([@B77]).

Neurobiology of Panic Attacks
-----------------------------

In recent years, the field of neurobiology has made significant progress to unravel brain regions and networks involved in PD. PD is classified as anxiety disorder, but research indicates that anxiety, fear, and panic are distinct entities. In a seminal human functional imaging study ([@B73]), individuals underwent a virtual predator paradigm. At a large distance, brain activation was mostly observed in the prefrontal cortex, which is associated with complex risk assessment and approach behavior. With decreasing distance brain activity shifted to the brainstem, a subcortical region associated with faster and more primitive responses such as fight-or-flight behavior. The predominant emotions that can be mapped to this "defensive distance" to a threat are anxiety and fear, respectively ([@B9]; [@B70]). Extending this model, conceptually, the smallest possible distance to a threat is one coming from within the body.

A threat from within the body can be caused by an acute disbalance in the pH homeostasis. CO~2~ is a stimulus that can cause such a brief disturbance. We propose that this triggers panic and is primarily coupled to activation of the primordial brainstem. If PAs are linked to primordial brain regions and fundamental mechanisms, it can be expected that every individual reacts to CO~2~. In line with this, we showed that also healthy individuals experience the fear and symptoms associated with PAs, when the dosage is increased compared to PD patients ([@B98]; [@B61]). This suggests that PD patients are hypersensitive to CO~2~. It remains to be determined which basic mechanism shifts physiological CO~2~-sensitivity to pathological as in PD. A starting point is provided by a functional imaging study by our group ([@B31]); in line with our proposition of the involvement of primordial brain regions, we demonstrated that CO~2~ activates the brainstem, in PD to a greater extent than in healthy participants. This indicates that brainstem abnormalities might underlie the hyperreactivity to CO~2~ in patients. Previously, the amygdala was proposed as center of the network involved in PD ([@B32]), and in determining fear behavior to CO~2~ in animal work ([@B118]). However, this concept recently got challenged by research in Urbach-Wiethe patients, who unexpectedly experienced experimental PAs to a CO~2~ inhalation despite having a bilaterally damaged amygdala ([@B26]). Our study provides additional evidence that other brain regions such as the brainstem could have a key role. The question remains which neurotransmitter systems and molecules are involved in detecting and reacting to CO~2~/pH changes. Among the many neurons sensitive to CO~2~/pH ([@B20]; [@B75]; [@B90]; [@B116]; [@B8]; [@B118]; [@B19], [@B18]), in context of PD, obvious candidates are proteins, neurons, and systems related to clinically effective medication. For example, Selective Serotonin Reuptake Inhibitors (SSRIs) target the serotonin transporter (5-HTT), suggesting a role of the 5-HT system in PD. As system functioning is affected by the expression of proteins, genetic research has drawn more attention in recent years.

The Role of Genetics
====================

A wealth of data suggests a role of the genome in the pathophysiology of PD. Family studies consistently revealed that the risk for PD is considerably increased in first-degree relatives ([@B17]; [@B40]; [@B78]; [@B65]; [@B71]; [@B114]; [@B30]). Additionally, the concordance rate for PD is higher for monozygotic, genetically identical twins than for dizygotic twins, suggesting that the disorder is genetically driven and not by shared environmental factors ([@B107]; [@B55]; [@B102]; [@B80]). Further, genetics also affects CO~2~-hypersensitivity, as demonstrated by first-degree family member studies, having an intermediate CO~2~ response between patients and unrelated healthy controls ([@B81]; [@B109]), and twin studies ([@B7]; [@B4], [@B5]; [@B92]).

To determine distinct genes that drive the risk for PD, hypothesis-free association and candidate approaches, the latter based on prior evidence for a role in the disease, have been used. Several hundred genes have been studied to date, extensively reviewed previously ([@B67]). Here, we very briefly focus on the 5-HT system and the amiloride-sensitive cation channel 2 (ACCN2), for which rodent and human work provided support. A length polymorphism in the promoter region of the 5-HTT, the serotonin transporter gene-linked polymorphic region (5-HTTLPR), affects the 5-HTT expression level ([@B62]). The short S-allele has a two- to threefold lower expression of the 5-HTT than the long L-allele, associated with a differential 5-HT signaling. While positive associations were reported regarding differential allele frequencies in patients compared to controls ([@B68]; [@B106]), other studies ([@B38]; [@B112]), including a meta-analysis (1,025 patients, 1,568 controls) controlling for ethnicity and comorbid agoraphobia could not confirm any association ([@B10]). However, some evidence suggests that the S-allele might be associated with more severe symptom severity ([@B64]) and the SS genotype with poor health-related quality of life ([@B51]). Regarding CO~2~-reactivity, healthy L-allele carriers of the 5-HTTLPR have a heightened fear response ([@B97]), which increases dose-dependently ([@B98]). However, in PD patients, CO~2~-reactivity was not affected by genotype ([@B82]). Yet, in the same study, it was observed that female L-allele carriers did respond better to SSRI treatment. Further, one study reported that no association could be found with the 5-HTTLPR but instead with other variants in the gene encoding the 5-HTT ([@B104]), suggesting that research should cover the entire gene and not solely focus on the promoter region. Mixed results were also found regarding genes expressing enzymes and receptors related to the 5-HT system. A recent meta-analysis ([@B48]) reported no association for tryptophan hydroxylase 2 (TPH2), the rate-limiting step in the synthesis of brain 5-HT, the 5HT1a receptor, 5-HT1b receptor, 5-HT2b receptor, and the 5-HT3a receptor. A nominal association was found in females regarding the 5-HT2a receptor and monoamine oxidase A (MAO-A), an enzyme involved in the breakdown of 5-HT, which however did not withstand multiple testing correction.

Furthermore, a role of the ACCN2 system is suggested by both rodent and human work. An association was reported between a variant in the ACCN2 gene and PD, but replication failed in an independent larger sample. However, a very heterogeneous sample with only a subset of PD patients might have masked the effects ([@B44]). A later large case-control study reported that a variant was associated with the diagnosis of PD ([@B103]). The functional consequences of this variant are unknown; authors speculated that it alters the sensitivity to detect and react to a reduced pH. This is a reasonable speculation as it was shown in rodents that the expressed ion channel is essential for CO~2~-induced fear-related behavior ([@B118]). In further support, we provided evidence that the variant is also associated with a differential response to CO~2~ in patients and healthy individuals ([@B60]).

Despite the progress in the past few decades, success in genetic research in anxiety disorders such as PD has proven difficult. Mental disorders like PD are very heterogeneous and complex, which make it necessary to study larger samples. One alternative approach is to focus on endophenotypes such as CO~2~-hyperreactivity or neurobiological responsiveness that are considered to depend on less genes than a complex disorder and can therefore be better linked to genes ([@B33]), thereby increasing the chances of detecting links between genetic variants and disease susceptibility.

Imaging Genetics
----------------

Modern neuroimaging techniques allow studying effects of genetic variants on neuronal activation to further examine the pathogenesis of PD.

A common approach is to present pictures with emotional value and to compare induced brain activation, as measured by functional magnetic resonance imaging, to the one caused by viewing neutral stimuli. With regard to the 5-HT system, in a small study with PD patients, no effect of the 5-HTTLPR was found on brain activation in response to fearful or angry facial stimuli ([@B22]). However, patients carrying the S-allele had an increased amygdala activation to happy faces. Contrary, in healthy individuals, fearful ([@B39]), and aversive stimuli ([@B41]) evoked increased amygdala activation in s-allele carriers. In addition, a greater coupling between the amygdala and the ventrolateral prefrontal cortex was found in these individuals, possibly linked to an altered capacity to regulate emotional states ([@B41]). Furthermore, in PD patients homozygous for a specific 5-HT1A variant, presentation of fearful faces reduced the activity of the right ventromedial prefrontal cortex, the right orbitofrontal cortex, and the right anterior cingulate cortex ([@B22]). No effect on amygdala activation was found. In a classical fear conditioning paradigm, in which repeated pairing of an initially neutral stimulus with an aversive event leads to a fear response to the previously neutral stimulus, PD patients with the "protective" low activity MAO-A allele had an increased anterior cingulate cortex activation to presentation of the paired neutral stimulus during the fear acquisition phase ([@B88]). In addition, carriers of the low activity allele also benefited more from cognitive behavioral therapy, as shown by a higher response percentage in this group. Regarding ACCN2, in addition to detecting that variants in this gene are associated with PD, an association of the PD-associated allele and bilaterally heightened amygdala volume and activity to visual presentation of emotional faces was also observed in healthy individuals ([@B103]).

Overall, these studies suggest that processing emotional stimuli might be affected by genetic variants and that altered activation in distinct brain regions might be linked to PD and the vulnerability to develop the disorder. Success of treatment strategies such as cognitive behavioral therapy could, also in part, depend on these factors. Delineating the mechanisms could lead to improved and more individualized treatments.

From Laboratory to Real-Life Assessment
=======================================

Ambulatory Assessment
---------------------

A general limitation of experimental models is the laboratory setting that does not reflect the natural environment. The highest ecological validity would be provided by studying PAs in a natural setting, i.e., in real-life outside the laboratory. This so-called ambulatory assessment consists of repeated within-day measurements of an individual's symptoms, behavior or physiology to monitor dynamic changes over time in relationship to the occurrence of PAs. Often a notification at specified or random time points throughout the day is given, requesting to fill out questions about presence and intensity of symptoms at that or near that moment. This momentary, real-time assessment is believed to reduce retrospective recall bias. However, to date, studies are relatively scarce, which is likely due to technical limitations such as a short battery life and very limited storage capacity in the past.

The conducted ambulatory assessment studies showed that palpitations, dizziness, dyspnea, nausea and sweating are among the most often experienced symptoms of real-life PAs ([@B66]; [@B46]). Of these, dyspnea, palpitations, dizziness and chest pain were the most intense one in another study ([@B72]). Comparing ambulatory ratings with retrospective questionnaires and structured diagnostic interviews revealed that patients had a distorted recollection and reported a greater number of symptoms, particularly fear of going crazy, faintness, trembling/shaking, and fear of dying. However, the ranking of symptom frequency remained similar ([@B66]).

Spontaneous PAs occurred most often at home ([@B66]) or when being with family or alone ([@B72]); situational ones most often in a car or public places ([@B66]). This can lead to significant behavioral changes. However, unexpectedly, patients with agoraphobia were not found to less often visit public places ([@B21]). Mean activity levels were higher in patients with a higher number of PAs, but there was no clear pattern if activity increased before or after attacks ([@B94]). Activity was also significantly higher when patients had no comorbid agoraphobia ([@B16]).

Given the pronounced physiological symptoms during PAs, attempts have been made to delineate cardio-respiratory changes. Early and newer studies observed an increase in heart rate in some self-reported PAs during 6- ([@B46]) to 24 h recordings ([@B3]; [@B27]; [@B12]), which could not be attributed to physical activity alone ([@B3]). Subjective severity of attacks correlated with heart rate. Contrary, in another study consisting of 175 PAs in 27 patients, heart rate did not increase during spontaneous attacks, but did in anticipation of or during experiencing situational attacks (i.e., in feared situations) ([@B66]), which is likely due to the anxiety component. Regarding breathing, PAs were associated with increased tidal volume ([@B69]; [@B72]), which positively correlated with the level of anxiety and fear of dying ([@B72]). Transcutaneous arterial CO~2~ levels were reported to decrease ([@B45]), which in a later study was observed in only one out of 24 situationally provoked PAs ([@B29]). Furthermore, in a rare case study in a dialysis patient, a spontaneous PA occurred with a strong reduction in arterial CO~2~ and pH increase ([@B95]). Focusing on PD and trait pathophysiological characteristics as a whole did not reveal any differences between patients and controls ([@B83]), also not during various levels of activity ([@B84]), suggesting that changes might be limited to more intense phases.

Considering potential interventions, it is particularly interesting to determine factors that precede the onset of PAs. PD patients seem not to be aware of any symptoms before PAs occur ([@B54]), and no increase in anticipatory anxiety was observed (measurement intervals of at least 2 h) ([@B42]). PA expectancy (morning measurement) was also not associated with a higher likelihood of having a PA ([@B72]); it only predicted subsequent anxiety ([@B93]). Subdividing PAs into unexpected and expected attacks showed that only expected attacks were preceded by an increased level of danger, anxiety, helplessness and a few symptoms ([@B54]). On the physiological level, strong autonomic irregularities do occur, as early as 47 min before PAs ([@B72]). More specifically, heart rate strongly increased the minute before the onset and was positively associated with fear of losing control. Skin temperature already increased in the hour preceding the attack, similarly, to a previous report that only measured the minutes around the attack and also observed an elevation ([@B27]). These observations suggest that physiological changes rather than subjective emotions are highly valuable to predict the impending occurrence of attacks and to intervene in the future.

Environment and Epigenetic Modifications
----------------------------------------

Increasing evidence suggest that neurotransmitter system functioning, such as of the 5-HT system, could be sensitive to environmental stimuli like stress ([@B47]). A mechanism of how environmental factors could affect system functioning is by altering DNA methylation ([@B36]), the best studied type of epigenetic modifications. These modifications are the regulatory interface of genes and vital for normal brain processes, including complex cognitive-affective functioning. Dysfunction can contribute to mental disorders. DNA methylation refers to the covalent binding of a methyl group to a cytosine's pyrimidine ring at position 5 (5-methylcytosine). This occurs more frequently at cytosines located next to a guanine nucleotide, forming a cytosine-phosphate-guanine (CpG) unit. Methylated CpG sites, which are overrepresented in regulatory promoter regions of genes, generally attract chromatin modifiers, disrupt binding of gene transcription factors and attract proteins that silence gene transcription ([@B57]). DNA methylation is carried out by DNA methyltransferases (DNMTs), families of specific enzymes ([@B43]). DNMT1 mainly functions as maintenance transferase to retain the current methylation pattern, while DNMT3a and DNMT3b catalyze *de novo* methylation. The role of the DNMT2 family remains unclear. DNA methylation is fairly stable, yet dynamic to environmental factors ([@B36]; [@B105]), suggesting that DNA methylation might be a mechanism of how environment factors affect gene expression ([@B36]). Demethylation takes place through several potential repair mechanisms. After oxidation of 5-methylcytosine to 5-hydroxymethylcytosine, subsequent base excision repair pathway ([@B37]) or DNMT3a and DNMT3b activity might lead to the removal of the hydroxymethyl group ([@B15]). Additionally, histone acetylation might actively demethylate DNA ([@B13]). Histones are proteins around which DNA is packed into larger nucleosomes. Acetylation takes place on the lysine residue within the N-terminal amino acid tail of histones, which affects chromatin structure and thereby gene accessibility.

DNA methylation can be affected by genetic variants ([@B111]) and environmental stimuli ([@B36]; [@B105]). Monozygotic twins who are genetically identical can thus still have different gene expressions and therefore differently functioning biological systems. This emphasizes the need for an integrative analysis of genes, epigenetics, and environment. To date, few epigenetic studies have been done in PD and most of these examined candidate genes. The MAO-A gene was found to be hypomethylated in a mixed sex patient group ([@B117]) and in another study in females ([@B23]). In the former study, hypomethylation negatively correlated with PD severity and normalized with effective cognitive behavioral therapy. *In vitro* studies showed that a decreased methylation is associated with an increased MAO-A expression ([@B14]). Regarding other neurotransmitter systems, hypomethylation of three CpG sites in the glutamate decarboxylases 1 gene, expressing the rate-limiting enzyme in GABA synthesis, has been found in PD patients ([@B24]). The assumed increased GABA level associated with hypomethylation might represent a compensatory mechanism that mediates the effects of negative life events. An additional gene, in which hypomethylation was found in PD patients is the gene expressing the corticotropin releasing hormone receptor 1 (CRHR1a) ([@B96]). This receptor is essential in the hypothalamic-pituitary-adrenal axis and also affects stress responses by innervating the locus coeruleus. As some studies reported that the majority of PD patients experienced a major life event in the months before the initial PAs ([@B108]), the receptor may be the link between stressful life events, stress responses and the risk for PD. Further, in a small case-control study minor methylation variation was found regarding the norepinephrine transporter gene (SLC6a2) ([@B6]). In contrast to these neurotransmitter system-related studies, another research line focuses on the role of the immune system in PD. The transcription factor gene Forkhead-Box-Protein P3 (FoxP3) appeared to be hypermethylated in female PD patients ([@B86]). This hypermethylation is assumed to be associated with reduced regulatory T-cells gene transcription, which leads to increased T-cell activation and thus inflammation. This could contribute to the higher rates of inflammatory disorders in PD patients.

Very recently, the first two epigenome-wide association studies (EWAS) were published. [@B101] found 40 CpG sites that were significantly associated with PD. Most of them were hypomethylated and pathway analysis revealed genes in epidermis development, cell cycle regulation, and lymphocyte activation. Examination of some candidate genes such as MAO-A, GAD1 and SLC6a2 did not show any association with PD. However, smoking and medication were not considered, which are known to affect methylation. The second EWAS study consisted of a larger sample, and an independent replication study ([@B49]). In females, after multiple testing correction, a differential methylation was found in the Homo sapiens headcase homolog (HECA) gene, a regulator in the cell cycle and with a potential role in cancer. Its link with PD has yet to be determined. Inclusion of 15 candidate genes showed significant associations with the 5-HT1a receptor in women and 5-HT2a receptor in men, but not GAD1 and CRHR1A as in previous studies. As smoking was not included as potential confounder, these results warrant replication.

The Need for an Interdisciplinary Approach and Future Perspectives
==================================================================

Experimental panic provocation studies have led to important insights into the nature of PAs in the last few decades. Ambulatory assessment studies are likely to provide further novel knowledge.

Both approaches address questions from different perspectives and bridging the gap between them is expected to open new opportunities, extending our understanding of PAs.

In experimental studies, the controlled environment and immediate effects of CO~2~ to induce PAs allows studying involved fundamental mechanisms in a temporally controlled manner. For example, (epi)genetic research and pharmacological manipulations can determine whether specific genes and neurotransmitter systems play a role in the sensitivity to CO~2~ and thus presumably PAs. This can strongly contribute to develop new and better treatment options. A major advantage of experimental studies compared to other types such as clinical or epidemiological studies is that induced effects are larger accompanied with smaller variation, making smaller samples sufficient to detect relevant effects. While it has been shown that the fear and symptoms triggered by a CO~2~ inhalation are a good representation of a real-life PA ([@B99]), a drawback is that attacks do not occur spontaneously in a natural environment but are provoked in a laboratory. The setting, procedure, and presence of the experimenter can affect individuals' responses, raising the question to which extent findings can be generalized to daily life.

In contrast to looking at acute effects in the laboratory, assessment of naturally occurring PAs in PD patients' daily lives provides the powerful opportunity to unravel the dynamic course over time. This approach has a higher ecological validity than laboratory models. A drawback is that prolonged recordings are required for comprehensive monitoring, which has been limited by the rather small storage capacity and short battery life of previous devices. The discomfort associated with carrying large setups also restricted sampling to small study samples in the past, but recent advances have led to small devices such as smartwatches that can be worn without being perceived as bothersome. Modern devices also have built-in actigraphy to quantify rest and activity patterns and to record body position, thereby providing more detailed situational data. Incorporating these and other measurements such as physiological parameters, and thereby moving from a main focus on patient ratings (e.g., feelings and symptoms) to automatic assessment, could help to develop interventions targeting the phase preceding attacks and to empower patients to use the device's feedback for self-directed changes in behavior. This approach puts the individual patient into the center and stimulates informed decisions. Likewise, ambulatory assessment is also suited to test the efficacy of treatments in real life. In the long-term, monitoring after successful treatment could identify individuals at risk to relapse and initiate early prevention. Using advanced devices measuring a broad spectrum of parameters, from physiology to context, can help to determine how symptoms are interrelated and interact with natural environmental factors that are controlled in a laboratory setting.

Environmental factors individuals are exposed to in real-life can affect molecular mechanisms such as epigenetic modifications and thus gene expression. Therefore, it is important to strive for an integrative, interdisciplinary approach of daily-life and fundamental research. For instance, determining which environmental factors are related to the disease and what their functional effects are on a molecular level could provide highly valuable insights into the pathophysiology of PAs. A major challenge is to identify the relevant environmental factors. In this respect, cumulative environmental risk scores combined with genotypes and epigenetic pattern could provide vastly informative data about which interactions are relevant and potentially identify risk groups to develop the disorder. Nowadays it is possible to cost-effectively determine epigenetic pattern in high-resolution, i.e., site-specific DNA methylation. However, these analyses require multiple testing correction for each CpG site, letting many sites fail to reach significance. An approach to tackle this issue could be the development of a novel correction methods similar to the ones applied in genome-wide association studies ([@B63]), taking into account the often highly correlated methylation levels of adjacent CpG sites to reduce the number of tests.

Moreover, most epigenetic PD studies to date were association studies, which do not allow drawing any conclusions about the exact role of DNA methylation. One approach to imply a causal role is the two-step Mendelian randomization method, in which first the causal impact of a risk factor on DNA methylation is examined, followed by testing the causal effect of DNA methylation on the outcome ([@B89]). Experimentally, large longitudinal studies can determine whether methylation changes over time are associated with developing the disorder. In this context, rodent models could be a highly beneficial addition as they allow molecular manipulations that exceed ethical possibilities in humans. For instance, studying behavioral consequences to central infusion of pharmacological compounds that target molecules of the epigenetic machinery and thereby lead to overwriting DNA methylation patterns could strengthen causality assumptions ([@B113]). At the same time, environmental factors can be controlled to assess their effects. We and others have analyzed rodents' behavioral performance under CO~2~ exposure ([@B118]; [@B50]; [@B59]). Adding for example cardio-respiratory monitoring as outcome variables, which can also be done in humans, further enhances the similarity between experiments and increases the translational value ([@B59]). We recently provided a quantitative comparison between rodents, healthy volunteers, and PD patients and showed that the physiological response in mice corresponds well to the one in both human groups ([@B59]). Such a model overcomes the challenge to align observed behavioral performances in rodents with behavioral self-reports in humans and maximizes translation of data between species. This can significantly drive forward research and eventually application of discoveries. For instance, once causality is suggested, efforts could focus on developing pharmacological compounds targeting epigenetic enzymes to normalize methylation pattern in rodents. Compensatory genes could be activated to reduce symptoms or even obtain a biochemical balance to eventually let patients fully recover. A caveat is that complex disorders are most likely caused by a network disturbance rather than a single gene, but such a starting point might inspire new directions and eventually brings us closer to better treatments.

Conclusion
==========

The manifestation of PAs can vary widely between people. To better understand the dimensional physiology and pathology and to facilitate a new classification in line with the RDoC project a more interdisciplinary approach of genome × epigenome × environment interactions is needed. Overall, integrating fundamental and real-life research can greatly advance the field, determine biomarkers to identify individuals at risk, and support developing more effective treatment strategies.
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